Skip to main content
Equibles

LMR Partners LLP

Position in REPL — Replimune Group, Inc.

CIK 1578621 LONDON, X0
Back to REPL Full portfolio

Position in REPL

as of Jun 30, 2026 · filed Aug 14, 2026
Position Value
$561,237
+$96,737 QoQ
Shares Held
50,699
+1.4% QoQ
Ownership
0.054%
of shares outstanding
% of Portfolio
0.01%
of 13F equity value
Holder Rank
#76
of 199 holders
Holding Since
Dec 2023
6 quarters on record
Voting authority Sole 100% Shared 0% None 0%

Common Shares in REPL Over Time

Shares Held

Position Value (USD)

Derivatives in REPL

reported options exposure · as of Jun 30, 2025
CallValue
$0
CallShares
0
PutValue
$53,882
PutShares
5,800

Notional value of option positions as reported on Form 13F. Calls and puts are disclosed separately and do not net against the common-share stake above.

Position in Biotechnology

Healthcare · as of Jun 30, 2026

LMR Partners LLP holds $188,560,243 across 75 Biotechnology names. REPL ranks #42 (0.3% of the industry book) .

# Ticker Company Shares Value (USD) Open
1 ALNY
Alnylam Pharmaceuticals, Inc.
 134,214 $40,402,439
2 DNTH
Dianthus Therapeutics, Inc. /DE/
 223,995 $21,835,032
3 REGN
Regeneron Pharmaceuticals, Inc.
 22,306 $13,908,683
4 TNGX
Tango Therapeutics, Inc.
 347,106 $10,850,533
5 RVMD
Revolution Medicines, Inc.
 5,112,098 $8,521,240
6 ARGX
Argenx SE
 8,200 $7,607,714
7 DFTX
Definium Therapeutics, Inc.
 150,200 $7,065,408
8 NKTR
Nektar Therapeutics
 100,000 $6,981,000

All Filings in REPL

Export CSV
8 filing rows on record
Report Date Value (USD) Shares
2026-06-30 $561,237 50,699
2025-06-30 $464,500 50,000
2025-06-30 $53,882 5,800
2024-09-30 $903,969 82,479
2024-06-30 $302,031 33,559
2024-03-31 $370,101 45,300
2023-12-31 $548,793 65,100
2023-12-31 $8 1